CO-1686 hydrobromide

• CAT Number: I001719
• CAS Number: 1446700-26-0
• Molecular Formula: C27H29BrF3N7O3
• Molecular Weight: 636.46
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• Solubility: DMSO: ≥ 59 mg/mL
• Storage: Store at -20°C
• IC50: 21.5±1.7 nM (EGFRL858R/T790M), 303.3 ± 26.7 nM (EGFRWT)
• IUPAC Name: N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide;hydrobromide
• InChI: InChI=1S/C27H28F3N7O3.BrH/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38;/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35);1H
• InChIKey: IPKRDUJIGYXXNT-UHFFFAOYSA-N
• SMILES: CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC.Br

CO-1686 Hydrobromide(CAT: I001719) is a potent and selective inhibitor of mutant epidermal growth factor receptor (EGFR) variants, including T790M, a key driver of resistance in non-small cell lung cancer (NSCLC). This compound demonstrates high efficacy in suppressing EGFR signaling, promoting apoptosis, and inhibiting tumor growth in preclinical models. CO-1686 Hydrobromide’s specificity for mutant EGFR over wild-type minimizes off-target effects, making it valuable for studying resistance mechanisms and developing targeted therapies. Ideal for cancer research, this inhibitor offers reliable performance in elucidating EGFR-related pathways and advancing the design of next-generation therapeutics for EGFR-mutant cancers.